Detecting Cancer Patents (Class 435/6.14)
  • Patent number: 9567641
    Abstract: A target substance used for combination treatment with an anti-c-Met antibody, a pharmaceutical composition for combination administration for preventing and/or treating cancer including an anti-c-Met antibody and an inhibitor against the target substance as active ingredients, a method for preventing and/or treating cancer including co-administering an anti-c-Met antibody and an inhibitor against the target substance, and a method for screening a drug for preventing and/or treating cancer using the target substance.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: February 14, 2017
    Assignees: SAMSUNG ELECTRONICS CO., LTD., GEORGETOWN UNIVERSITY
    Inventors: Bo Gyou Kim, Shangzi Wang, Ji Min Lee, Kyung Ah Kim, Louis M. Weiner
  • Patent number: 9556491
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: January 31, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Patent number: 9551036
    Abstract: Aspects of the invention relate to methods and compositions for characterizing or modulating the expression of metabolic mesenchymal genes. In some embodiments, methods for assessing the expression of metabolic mesenchymal genes and related gene signatures are provided that are useful for cancer classification, prognosis, diagnosis, or treatment selection.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: January 24, 2017
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Yoav D. Shaul, David M. Sabatini
  • Patent number: 9550989
    Abstract: The present disclosure encompasses methods for rational design of microRNA and small interfering RNA chimeras and compositions and methods of use thereof.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: January 24, 2017
    Assignee: WASHINGTON UNIVERSITY
    Inventor: Xiaowei Wang
  • Patent number: 9545630
    Abstract: Provided is a method for fabricating a microchip for nucleic acid amplification reaction that is capable of simple and highly accurate analysis. Provided is a method for fabricating a microchip for nucleic acid amplification reaction, the method including a solidification step of drying a reagent solution including at least a part of substances required for a nucleic acid amplification reaction, and a containment step of arranging the reagent solution including the solidified substance in wells that serve as a reaction site for a nucleic acid amplification reaction. In the microchip for nucleic acid amplification reaction fabricated by the fabrication method, since substances required for the nucleic acid amplification reaction are contained by being solidified, non-specific amplification is suppressed in a nucleic acid amplification reaction, which enables highly accurate analysis.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: January 17, 2017
    Assignee: Sony Corporation
    Inventors: Masahiro Matsumoto, Masaki Sato, Hidetoshi Watanabe
  • Patent number: 9540696
    Abstract: The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: January 10, 2017
    Assignees: Stichting Katholieke Universiteit, The University Medical Centre Nijmegen, The Johns Hopkins University
    Inventors: Marion J. G. Bussemakers, William B. Isaacs
  • Patent number: 9541555
    Abstract: This invention relates to a screening method for the identification of agents which modulate the activity of a DNA replication protein as a target for intervention in cancer therapy and includes agents which modulate said activity. The invention also relates to the use of the DNA replication protein, and its RNA transcripts in the prognosis and diagnosis of proliferative disease e.g., cancer.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 10, 2017
    Assignee: Cizzle Biotech Limited
    Inventor: Dawn Coverley
  • Patent number: 9541545
    Abstract: The present invention comprises rugged, inexpensive, reliable, and sensitive laboratory assays of antibody-based viral neutralization activity and antibody-based viral adherence inhibition activity. The assays use inactivated, fluorescently-labeled virus, allowing the tests to be performed without extensive safety precautions. The interaction of the labeled virus with target cells is monitored using flow cytometric methods. A preferred embodiment uses simple and inexpensive flow cytometry methodologies and equipment, such as bead array readers used as simplified flow cytometers. The assays are rapid, taking no longer than a few hours and are readily conducted by a trained technician. The assays are sensitive because they use labeled viruses at low concentrations and determine neutralizing and blocking capacity of sera and antibody at low concentrations. The methods are appropriate for high-throughput screening of large panels of samples.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: January 10, 2017
    Assignee: SANOFI PASTEUR VAXDESIGN CORPORATION
    Inventors: Anatoly Kachurin, Olga Kachurina, Vaughan Wittman, Tenekua Tapia
  • Patent number: 9540694
    Abstract: The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia, in particular breast neoplasia. The invention is based in part on the observation that the basic helix loop helix transcription factor HEYL was found to be overexpressed in breast cancer cells. Accordingly, the invention provides therapeutic compositions and methods for altering the levels and expression of HEYL of the invention, thereby treating a neoplasia, as well as compositions and methods for diagnosing a neoplasia.
    Type: Grant
    Filed: May 21, 2007
    Date of Patent: January 10, 2017
    Assignee: The Johns Hopkins University
    Inventors: Saraswati Sukumar, Liangfeng Han
  • Patent number: 9534256
    Abstract: The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.
    Type: Grant
    Filed: January 6, 2012
    Date of Patent: January 3, 2017
    Assignees: Wake Forest University Health Sciences, The Johns Hopkins University
    Inventors: Jianfeng Xu, William B. Isaacs, Henrik Grönberg
  • Patent number: 9527916
    Abstract: The invention relates to a binding compound, which binds the same epitope of human CD27 as monoclonal antibody hCD27.15, produced by hybridoma hCD27.15 which was deposited with the ATCC in on Jun. 2, 2010 under number PTA-11008. In particular the invention relates to such a binding compound of claim 1 which may comprise: an antibody heavy chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 5, 6 and 7, or a variant of any of said sequences; and/or an antibody light chain variable region which may comprise at least one CDR selected from the group consisting of SEQ ID NOs: 8, 9 and 10, or a variant of any of said sequences.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: December 27, 2016
    Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
    Inventors: Hans Van Eenennaam, Winfried Robert Mulder, Jannetje Geertruida Borst, Aartje Maria Elizabeth Veraar, Paul Maria Frederikus Vink
  • Patent number: 9528111
    Abstract: The invention provides a single-stranded nucleic acid molecule containing an expression inhibitory sequence that inhibits expression of a target gene, region (X), linker region (Lx), and region (Xc), wherein the linker region (Lx) is linked between the region (Xc) and the region (Xc), the region (Xc) is complementary to the region (X), at least one of the region (X) and the region (Xc) contains the expression inhibitory sequence, and the linker region (Lx) contains an atomic group derived from an amino acid. The single-stranded nucleic acid molecule can inhibit expression of the target gene.
    Type: Grant
    Filed: December 29, 2012
    Date of Patent: December 27, 2016
    Assignee: Bonac Corporation
    Inventors: Tadaaki Ohgi, Hiroshi Suzuki, Tomohiro Hamasaki, Eriko Aoki
  • Patent number: 9522171
    Abstract: The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus (SARS), pandemic Influenza A H5N1 (avian influenza) and pandemic influenza A H1N1 (swine 'flu).
    Type: Grant
    Filed: January 2, 2015
    Date of Patent: December 20, 2016
    Assignee: Volution Immuno Pharmaceuticals SA
    Inventor: Wynne Weston-Davies
  • Patent number: 9518297
    Abstract: The invention relates to a method for a more appropriate thromboembolic event risk assessment based on the presence of different genetic variant. The invention also relates to a method for determining the risk of suffering a thromboembolism disease by combining the absence or presence of one or more polymorphic markers in a sample from the subject with conventional risk factors for thromboembolism as well as computer-implemented means for carrying out said method.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: December 13, 2016
    Assignee: Gendiag.exe, S.L.
    Inventors: Eduardo Salas, José Manuel Soria, Miroslava Ogorelkova, Roberto Elosua Llanos, Joan Vila, Sergio Castillo
  • Patent number: 9518125
    Abstract: Provided is method of diagnosing liver cancer in a subject, the method comprising contacting a sample from a subject with a substance that specifically binds to transmembrane emp24 domain trafficking protein 2 (TMED2), cluster of differentiation 43 (CD43), or any combination thereof on the surface of a microvesicle; and measuring the level of the substance bound to microvesicles in the sample; and related methods and compositions.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 13, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Ye-ryoung Yong, Hyun-ju Kang, Ga-hee Kim, Kyung-hee Park, Jong-myeon Park
  • Patent number: 9512235
    Abstract: The present invention relates to an antibody being capable of binding specifically to BC200 RNA or its antigen binding fragment, a polynucleotide of encoding the antibody or its antigen binding fragment, a composition, kit and method for detecting BC200 RNA in a sample using the antibody or its antigen binding fragment, and a composition for diagnosis, prevention or treatment of BC200 RNA-associated diseases including the antibody or its antigen binding fragment.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: December 6, 2016
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Younghoon Lee, Euihan Jung, Jung Min Lee, Insoo Park, Hyo Jeong Hong
  • Patent number: 9512444
    Abstract: The present invention provides methods and kits for editing specific chromosomal sequences in cells. In particular, targeting endonucleases and single-stranded nucleic acids are used to edit the chromosomal sequence.
    Type: Grant
    Filed: July 22, 2011
    Date of Patent: December 6, 2016
    Assignee: Sigma-Aldrich Co. LLC
    Inventors: Fuqiang Chen, Shondra M. Pruett-Miller, Gregory D. Davis
  • Patent number: 9506062
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: November 29, 2016
    Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Patent number: 9493804
    Abstract: The present invention relates to a nucleic acid molecule for recombinant expression and secretion of a peptide or protein of interest comprising a hemolysin A and/or hemolysin C-derived nucleotide sequence, fragments thereof, homologs thereof, or the complements thereof, and a nucleotide sequence encoding the peptide or protein of interest.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: November 15, 2016
    Assignee: Heinrich-Heine-Universitaet Duesseldorf
    Inventors: Christian Schwarz, Lutz Schmitt, Sander Hendrikus Joannes Smits
  • Patent number: 9493842
    Abstract: Disclosed are methods of determining the prognosis of thymic cancer in a subject comprising detecting a mutation in the general transcription factor IIi (GTF2I) genetic sequence or protein. The presence of a GTF2I mutation indicates that the thymic cancer is indolent.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: November 15, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Giuseppe Giaccone, Yisong Wang, Iacopo Petrini
  • Patent number: 9486449
    Abstract: The subject invention provides for cancer therapy.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: November 8, 2016
    Inventor: Malka Cohen-Armon
  • Patent number: 9487493
    Abstract: The present invention provides methods for treating muscle atrophy by administering a PPAR? agonist.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: November 8, 2016
    Assignee: vTv Therapeutics LLC
    Inventors: Maria Carmen Valcarce Lopez, Eliot Ohlstein
  • Patent number: 9486545
    Abstract: The present invention relates to biomarkers for colon cancers, specifically adenomas and adenocarcinomas in the GI tract. The inventors have discovered that the expression and/or overexpression of biomarkers such as CLDN1, GPR56, GRM8, LY6G6D, TLR4 and SLCO1B3 are indicative of adenomas and adenocarcinomas. A method of detecting colon cancer using targeted molecular imaging agents is also presented.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: November 8, 2016
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: David L. Morse, Robert J. Gillies
  • Patent number: 9481890
    Abstract: A method of modifying morphology in a plant comprising introducing into a plant at least one chimaeric gene comprising a promoter sequence operably associated with a nucleic acid sequence, the promoter sequence being operable to direct expression in specific cells of the plant and the nucleic acid sequence encoding at least one gene product capable of altering the metabolism of or causing death of the specific cells and/or nearby cells. In particular, the promoter sequence is operable to direct expression in lateral bud or lateral shoot and the nucleic acid encoding at least one gene product capable of disrupting the metabolism of or causing the death of the lateral bud or lateral shoot or nearby cells. Preferably the promoter sequence comprises the sequence shown as SEQ ID No. 1 or SEQ ID No. 7 or SEQ ID No. 4, or a part thereof capable of regulating expression of a gene, or a sequence having at least 60%, preferably at least 75%, homology to SEQ ID No. 1 or SEQ ID No.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: November 1, 2016
    Assignee: British American Tobacco (Investments) Limited
    Inventors: Christopher John Robert Thomas, Martin Richard Ward
  • Patent number: 9481885
    Abstract: The present invention provides materials and methods related to the discovery that tumor secreted miR-21 and miR-29a can function by binding as ligands to receptors of the Tolllike receptor family, murine TLR7 and human TLR8, in immune cells, triggering a TLR-mediated prometastatic inflammatory response, which leads to tumor growth and metastasis. Thus, by acting as paracrine agonists of TLRs, secreted miRNAs are key regulators of the tumor microenvironment. This mechanism of action of miRNAs is important in the tumor-immune system communication, in tumor growth and spread, and in cancer treatment.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: November 1, 2016
    Assignee: Ohio State Innovation Foundation
    Inventors: Carlo M. Croce, Muller Fabbri
  • Patent number: 9469875
    Abstract: The present invention relates generally to the detection or diagnosis of depressive disorders, and provides methods and compositions useful for this purpose. In particular, the present invention provides biomarkers for the detection or diagnosis of major depressive disorder, and methods of use thereof.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: October 18, 2016
    Assignee: Northwestern University
    Inventors: Eva Redei, Brian Andrus
  • Patent number: 9458456
    Abstract: Some embodiments of the present technology relate to methods and compositions for the diagnosis and treatment of cancer. Some embodiments include methods and compositions for the diagnosis and treatment of castration-resistant prostate cancer. Some embodiments include methods and compositions for the diagnosis and treatment of pancreatic cancer.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: October 4, 2016
    Assignee: UNIVERSITY OF SOUTH ALABAMA
    Inventors: Ajay Pratap Singh, Sanjeev Srivastava, Seema Singh
  • Patent number: 9447146
    Abstract: Guanylin cyclase C compound of the inventions are disclosed. Conjugated compounds comprising guanylin cyclase C compound of the inventions conjugated to detectable or therapeutic moieties are disclosed. Methods of detecting, imaging and treating cancer and treating diarrhea are disclosed.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: September 20, 2016
    Assignee: Thomas Jefferson University
    Inventors: Hank Wolfe, Scott A. Waldman
  • Patent number: 9447471
    Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: September 20, 2016
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
  • Patent number: 9441046
    Abstract: Provided herein is are methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Patent number: 9441047
    Abstract: Provided herein are methods of improving asthma symptoms, e.g., as measured by an asthma control questionnaire, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Patent number: 9441037
    Abstract: Provided herein is are methods of reducing exacerbations of asthma in an asthma patient, comprising administering to the patient an effective amount of the anti-interleukin-5 receptor (IL-5R) antibody benralizumab or an antigen-binding fragment thereof.
    Type: Grant
    Filed: August 7, 2014
    Date of Patent: September 13, 2016
    Assignee: ASTRAZENECA AB
    Inventors: Christine Ward, Lorin Roskos, Bing Wang, Donald Raible
  • Patent number: 9435001
    Abstract: The invention describes a consensus PCR based method (i.e. HRE7-PCR) for the simultaneous detection of 14 Human Papilloma Virus types (i.e. HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are classified as (probably) high-risk, relating to the causation of cervical cancer) and a candidate hrHPV type (i.e. HPV 67) using sets of 6 overlapping forward primers and 9 overlapping backward primers that together amplify a fragment of about (215) to (245) base pairs of the E7 open reading frame of these hrHPV types. For the detection of reaction products an EIA format can be used with the aid of a cocktail of type-specific oligoprobes as exemplified herein. Furthermore, we have developed a method for an efficient typing of these (15) HPVs that is compatible with the method for detection. This RLB typing system involves hybridization of PCR products with immobilized type-specific oligoprobes.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: September 6, 2016
    Assignee: SELF-SCREEN B.V.
    Inventors: Christophorus Joannes Lambertus Maria Meijer, Petrus Josephus Ferdinandus Snijders
  • Patent number: 9434980
    Abstract: A method is disclosed for concentrating sample constituents and for multiplying nucleic acids from a biological sample which are containing in the sample constituents. The nucleic acids are amplified on the same filter on which the sample constituents are also separated off.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: September 6, 2016
    Assignee: ROBERT BOSCH GMBH
    Inventors: Peter Rothacher, Jan Weile, Susanne Muench, Martina Daub
  • Patent number: 9434992
    Abstract: Provided are a diagnosis marker, a diagnosis method, and a therapeutic agent suitable for diagnosing and treating amyotrophic lateral sclerosis (ALS). Also provided are an animal model and a cell model suitable for developing a therapeutic agent and a treatment method for ALS. The diagnosis method for ALS includes: an isolation step in which a nucleic acid is isolated from a specimen taken from a subject; a detection step in which bases expressed in a human chromosome 10 optineurin (OPTN) gene region are detected from the isolated nucleic acid; and a determination step in which it is determined whether or not the detected bases are mutated.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: September 6, 2016
    Assignee: HIROSHIMA UNIVERSITY
    Inventors: Hideshi Kawakami, Hirofumi Maruyama, Hiroyuki Morino
  • Patent number: 9428845
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: August 30, 2016
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • Patent number: 9422606
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.
    Type: Grant
    Filed: October 21, 2010
    Date of Patent: August 23, 2016
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: Feras Hantash
  • Patent number: 9422551
    Abstract: An improved adapter design for ligation to target RNA in a library is described which enables target RNAs that would normally be under-represented or not represented at all in a cDNA library or a PCR product of the cDNA library, to be represented with average frequency.
    Type: Grant
    Filed: May 29, 2013
    Date of Patent: August 23, 2016
    Assignee: New England Biolabs, Inc.
    Inventors: G. Brett Robb, Ryan T. Fuchs, Fanglei Zhuang
  • Patent number: 9416410
    Abstract: The present invention is related to an improved method for HER2 gene test by using quantitative real-time PCR (Polymerase Chain Reaction) technique. Our invention streamlines test process, and incorporates quality control for each major step, including sample, reagent, operation, and data report. We eliminate the need for reference genes which is hard to standardize in HER2 PCR test. We develop a cutoff reference point by using the statistical mean of tumor tissue population, and adopt a simplified scoring scheme for evaluation of HER2 status. Our invention produces consistent result across machines and labs, and has proven to be clinically successful in HER2 test.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: August 16, 2016
    Assignee: Genetics Development Corporation
    Inventors: Rong Yu, Kung-ying Chiu, Shau-zou Lu
  • Patent number: 9403141
    Abstract: De novo synthesized large libraries of nucleic acids are provided herein with low error rates. Further, devices for the manufacturing of high-quality building blocks, such as oligonucleotides, are described herein. Longer nucleic acids can be synthesized in parallel using microfluidic assemblies. Further, methods herein allow for the fast construction of large libraries of long, high-quality genes. Devices for the manufacturing of large libraries of long and high-quality nucleic acids are further described herein.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: August 2, 2016
    Assignee: TWIST BIOSCIENCE CORPORATION
    Inventors: William Banyai, Bill James Peck, Andres Fernandez, Siyuan Chen, Pierre Indermuhle
  • Patent number: 9382537
    Abstract: The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: July 5, 2016
    Assignee: ASURAGEN, INC.
    Inventors: David Brown, Lance Ford, Angie Cheng, Rich Jarvis, Mike Byrom, Dmitriy Ovcharenko, Eric Devroe, Kevin Kelnar
  • Patent number: 9371565
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with psoriasis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, such as a haplotype, a diplotype, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: June 21, 2016
    Assignee: Celera Corporation
    Inventors: Ann Begovich, Ellen Beasley, Michelle Cargill, Steven Schrodi
  • Patent number: 9340830
    Abstract: A method of analyzing a tumor sample comprising: (a) acquiring a library comprising a plurality of tumor members from a tumor sample; (b) contacting the library with a bait set to provide selected members; (c) acquiring a read for a subgenomic interval from a tumor member from said library; (d) aligning said read; and (e) assigning a nucleotide value (e.g., calling a mutation) from said read for the preselected nucleotide position, thereby analyzing said tumor sample.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: May 17, 2016
    Assignee: FOUNDATION MEDICINE, INC.
    Inventors: Doron Lipson, Geoffrey Alan Otto, Alexander N. Parker, Philip James Stephens, Sean R. Downing, Mima Jarosz, Mikhail G. Shapiro, Roman Yelensky
  • Patent number: 9336298
    Abstract: Embodiments of the present invention relate to systems, methods, and computer-storage media for a method of contextually analyzing terms within a search query. In one embodiment, a received search query is classified into a domain category. Additionally, information is assigned to a schema associated with the domain by analyzing the search query. Further, at least one search result that helps a user complete a task within the domain is provided based on the information in the schema.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: May 10, 2016
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Shipeng Li, Ye-Yi Wang, Xiaochuan Ni, Jian-Tao Sun, Zheng Chen, Zhimin Zhang, Xiaolong Li, Xuedong Huang, Li Jiang
  • Patent number: 9328383
    Abstract: The invention relates to a method for the high throughput discovery, detection and genotyping of one or more genetic markers in one or more samples, comprising the steps of restriction endonuclease digest of DNA, adaptor-ligation, optional pre-amplification, selective amplification, pooling of the amplified products, sequencing the libraries with sufficient redundancy, clustering followed by identification of the genetic markers within the library and/or between libraries and determination of (co-)dominant genotypes of the genetic markers.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: May 3, 2016
    Assignee: Keygene N.V.
    Inventors: Michael Josephus Theresia Van Eijk, Anker Preben Sørensen, Marco Gerardus Maria Van Schriek
  • Patent number: 9314434
    Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: April 19, 2016
    Assignee: Nogra Pharma Limited
    Inventors: Sergio Baroni, Salvatore Bellinvia, Francesca Viti
  • Patent number: 9297012
    Abstract: Methods for assessing a pathological condition in a subject include measuring one or more markers where a difference is indicative of acute lymphoblastic leukemia (ALL) or a predisposition to ALL, uses and compositions are disclosed.
    Type: Grant
    Filed: August 18, 2015
    Date of Patent: March 29, 2016
    Assignee: The Ohio State University Research Foundation
    Inventor: Carlo M. Croce
  • Patent number: 9296783
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: March 29, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Patent number: 9297038
    Abstract: Disclosed are a method and a kit for the quantification of nucleic acids, especially a trace amount of nucleic acid, such as host cell nucleic acid impurities, using real-time PCR with a random primer.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: March 29, 2016
    Assignee: KOREA RESEARCH INSTITUTE OF STANDARDS AND SCIENCE
    Inventors: In Chul Yang, Min Jung Kang, Han Nah Yu, Sang Ryoul Park, Sook Kyoung Kim
  • Patent number: 9238817
    Abstract: The present invention relates to a method for producing a protein of interest containing one or more disulfide bonds in its native state. The method comprises that a prokaryotic host cell is genetically engineered to express the protein of interest and a sulfhydryl oxidase in the cytoplasm of the host cell. The protein of interest is formed in a soluble form and contains disulfide bonds due to the presence of the sulfhydryl oxidase in the cytoplasm of said host cell. The present invention relates also to a prokaryotic host cell and a vector system for producing a protein of interest containing natively folded disulfide bonds.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: January 19, 2016
    Assignee: Univeristy of Oulu
    Inventor: Lloyd Ruddock